FRI0242 Impairment in the rates of incidence, mortality, stays and annual costs of hospitalizations for gout in the spanish national health system
2018
Background Gout is the most common inflammatory articular disease in adults concerning a 1%–2% of the general population, and even a 4%–5% in older than 70 years. Recently, it has been reported an increase of the prevalence of gout, especially in developed countries. Objectives The principal purpose of our study is to describe the clinical and epidemiological characteristics of hospitalised patients with diagnosis of gout in Spain including mortality, comorbidities and healthcare costs in the last decade Methods Retrospective observational study based on data from the Database of Hospital from the Spanish National Health Service. The study was conducted in patients over eighteen years old with any gout diagnosis as principal or other diagnosis, who were admitted in the hospital between the years 2005–2015. The clinical characteristics analysed were sex, age, costs and length of hospital stay. Comorbidities as diabetes, congestive heart failure, acute myocardial infarction and cerebrovascular disease were identified with International Classification of Diseases, ninth revision, common modification ( ICD-9-CM). Results The study cohort included 192.037 patients with gout, 82.6% of those were males. There was a progressive increase in the number of hospitalised patients with gout from 12 851 patients in 2005 to 23 318 in 2015; this was associated with an increase in mortality, reaching its highest value in 2015 with a 4.9% of gout hospitalised patients. The average age at dead in 2015 was 79.2 years and 85.16 years in male and female respectively, an age slightly lower than in the general population. The average cost in these hospitalised patients was 4931 €, reaching a peak of 5384 € in the last year. The hospital stay reached its lowest numbers in 2015 with an average of 8.9 days per patient. These comorbidities had statistical association with an added mortality risk in cerebrovascular disease (odds ratio [OR] 1.57, 95% confidence interval [CI]1.46–1.49), liver disease (OR 2.61 95% CI 2.34–2.9), kidney disease (OR 1.34 95% CI 1.28–1.41), dementia (OR 2.13 95% CI 1.88–2.42). On the contrary, in type 2 diabetes (OR 0.92 95% CI 0.87–0.96), we found a statistically significant lower mortality risk. Furthermore, it was found a statistically reduced mortality risk in females (OR 0.85 95% CI 0.8–0.9) Conclusions In Spain we have a progressive increase in the hospital admissions for gout, higher mortality rates and higher healthcare costs. This shows the need for changes in prevention and management of gout disease. Disclosure of Interest None declared
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI